Introduction
[Microglia](/entities/microglia) Modulation Therapies represent a cutting-edge approach in neurodegenerative disease treatment, targeting the resident immune cells of the central nervous system. This page provides comprehensive information about therapeutic strategies aimed at modulating microglial function to promote neuroprotection and reduce neuroinflammation in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders.
[@hansen2022]
Pathway Diagram
flowchart TD
microglia["microglia"]
TREM2_APOE_pathway["TREM2-APOE pathway"]
TREM2_APOE_pathway -->|"regulates"| microglia
TNF["TNF"]
TNF -->|"secreted_by"| microglia
TNF__["TNF-alpha"]
TNF__ -->|"secreted_by"| microglia
ULK1["ULK1"]
ULK1 -->|"expressed in"| microglia
neuroinflammation["neuroinflammation"]
neuroinflammation -->|"affects"| microglia
Alzheimer_s_disease["Alzheimer's disease"]
Alzheimer_s_disease -->|"affects"| microglia
aging["aging"]
aging -->|"affects"| microglia
style microglia fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style TREM2_APOE_pathway fill:#4a148c,stroke:#ce93d8,color:#ce93d8
style TNF fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style TNF__ fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style ULK1 fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style neuroinflammation fill:#4a0000,stroke:#ef5350,color:#ef5350
style Alzheimer_s_disease fill:#4a0000,stroke:#ef5350,color:#ef5350
style aging fill:#4a0000,stroke:#ef5350,color:#ef5350
...Introduction
[Microglia](/entities/microglia) Modulation Therapies represent a cutting-edge approach in neurodegenerative disease treatment, targeting the resident immune cells of the central nervous system. This page provides comprehensive information about therapeutic strategies aimed at modulating microglial function to promote neuroprotection and reduce neuroinflammation in Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders.
[@hansen2022]
Pathway Diagram
Mermaid diagram (expand to render)
Knowledge graph relationships for microglia (1675 total edges in KG)
Overview
[Microglia](/cell-types/microglia-neuroinflammation) are the primary immune cells of the brain and spinal cord, constituting approximately 10-15% of all cells in the central nervous system. These cells originate from yolk sac progenitors during embryonic development and self-renew throughout life under healthy conditions. In neurodegenerative diseases, microglia undergo dramatic phenotypic changes that can be either beneficial or detrimental to neuronal health. [@gray2023]
Dysregulated microglial activity contributes to neurodegeneration through multiple mechanisms, including chronic neuroinflammation, excessive synaptic pruning, and failed clearance of pathological protein aggregates. Modulating microglial function has emerged as a promising therapeutic strategy that may address upstream mechanisms of neuronal loss, potentially providing disease-modifying effects rather than merely symptomatic relief. [@zhang2022]
Microglia in Neurodegeneration
Beneficial Functions
Under normal conditions, microglia perform essential roles in brain homeostasis:
- Surveillance: Continuous monitoring of the brain environment through highly motile processes that extend and retract every few minutes, allowing rapid detection of any disturbances
- Phagocytosis: Clearance of debris, dead [neurons](/entities/neurons), and pathological protein aggregates including [amyloid-beta](/proteins/amyloid-beta-protein) plaques and [alpha-synuclein](/proteins/alpha-synuclein) inclusions
- Support: Release of neurotrophic factors including [BDNF](/proteins/bdnf-protein) (Brain-Derived Neurotrophic Factor) that support neuronal survival and synaptic plasticity
- Repair: Promotion of tissue remodeling and wound healing following injury
- Synaptic Pruning: During development, microglia eliminate excess synapses to refine neural circuits; this process becomes dysregulated in disease states
Detrimental Functions
In neurodegenerative diseases, microglia can adopt a hyperactivated state that promotes pathology:
- Chronic Inflammation: Sustained release of pro-inflammatory cytokines including [IL-1β](/proteins/interleukin-1-beta), [TNF-α](/proteins/tnf-alpha), and [IL-6](/proteins/interleukin-6) creates a neurotoxic environment
- Excessive Synaptic Pruning: Over-elimination of synapses correlates with cognitive decline in both Alzheimer's and Parkinson's disease
- [NLRP3](/proteins/nlrp3-protein) Inflammasome: Activation leads to caspase-1 activation and subsequent IL-1β and IL-18 production
- [TREM2](/proteins/trem2-protein) Dysfunction: Loss-of-function variants in TREM2 impair microglial phagocytosis of amyloid deposits and increase Alzheimer's disease risk
- Reactive Microgliosis: Proliferation and clustering around sites of pathology, sometimes forming donut-shaped structures around amyloid plaques
Therapeutic Approaches
TREM2 Targeting
[Triggering Receptor Expressed on Myeloid Cells 2](/proteins/trem2) (TREM2) is a surface receptor on microglia that recognizes lipid aggregates and apolipoproteins. Genetic variants in TREM2 significantly modify Alzheimer's disease risk.
TREM2 Agonists:
- AL002: Anti-TREM2 antibody designed to activate TREM2 signaling pathways, enhancing microglial phagocytic capacity
- AL003: TREM2-modulating antibody with different mechanism of action
- PY314: TREM2-targeting antibody in preclinical development
Mechanism: These antibodies enhance microglial phagocytosis of [amyloid-beta](/proteins/amyloid-beta) aggregates, promote the formation of disease-associated microglia (DAM) phenotype, and may reduce plaque burden
Clinical Status: Multiple Phase I and Phase II trials ongoing for Alzheimer's disease
References:
<sup><a href=#references>[1]</a></sup>^,^<sup><a href=#references>[2]</a></sup>^
CSF-1R Inhibition
Colony-Stimulating Factor 1 Receptor (CSF-1R) is critical for microglial survival, proliferation, and pro-inflammatory activation. Inhibition can reduce microglial numbers and inflammatory phenotype.
Purpose: Reduce microglial proliferation, decrease pro-inflammatory activation, and shift microglia toward a more protective phenotype
Drugs:
- PLX3397 (Pexidartinib): CSF-1R antagonist approved for tenosynovial giant cell tumor; being repurposed for neurodegenerative diseases
- PLX5622: CSF-1R inhibitor with excellent CNS penetration in preclinical studies
- BLZ945: Highly selective CSF-1R inhibitor showing promise in ALS models
Clinical Status:
- Preclinical studies demonstrate reduced neuroinflammation and improved outcomes in AD and PD models
- Several Phase I trials completed, Phase II trials ongoing for Alzheimer's disease and ALS
- Challenge: Balancing microglial depletion with loss of protective functions
References:<sup><a href=#references>[3]</a></sup>^
NLRP3 Inflammasome Inhibitors
The [NLRP3](/entities/nlrp3-inflammasome) inflammasome is a key driver of microglial inflammation, converting pro-IL-1β to active IL-1β through caspase-1 activation.
Purpose: Block IL-1β production and release from activated microglia, reducing chronic neuroinflammation
Drugs:
- MCC950: Potent and selective NLRP3 inhibitor; showed promise in preclinical models but development paused due to liver toxicity
- Dapansutrile (OLT1177): Oral NLRP3 inhibitor with improved safety profile; in clinical trials for inflammatory conditions
- Tranilast: Approved anti-allergic drug with NLRP3 inhibitory activity being repurposed
Clinical Status: Several candidates in Phase I/II trials for inflammatory conditions; neuro-specific trials planned
References:
<sup><a href=#references>[4]</a></sup>^
BTK Inhibition
Bruton's Tyrosine Kinase (BTK) is expressed in microglia and regulates multiple inflammatory signaling pathways.
Purpose: Modulate microglial activation through BTK pathway inhibition, reducing pro-inflammatory cytokine production
Drugs:
- Tolebrutinib (SAR442168): BTK inhibitor in late-stage clinical development
- Fenebrutinib (GDC-0853): Highly selective BTK inhibitor
Clinical Trials:
- Phase II/III trials for multiple sclerosis completed
- Phase II trials planned for Alzheimer's disease
- Demonstrated reduced microglial activation in PET imaging studies
References:<sup><a href=#references>[5]</a></sup>^
PPAR-γ Agonists
Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) is a nuclear receptor that regulates microglial inflammatory responses.
Purpose: Promote anti-inflammatory microglial phenotype and reduce neuroinflammation
Drugs:
- Pioglitazone: PPAR-γ agonist with demonstrated anti-inflammatory effects in preclinical models
- Diraglutide: [GLP-1 receptor](/entities/glp1-receptor) agonist with microglial modulatory effects
Clinical Status: Some evidence of reduced dementia risk in diabetic patients; clinical trials ongoing
Disease-Specific Applications
Alzheimer's Disease
Microglia play a central role in Alzheimer's disease pathophysiology:
- Amyloid Clearance: TREM2 variants affect the brain's ability to clear amyloid plaques; microglial clustering around plaques is a hallmark finding
- Neuroinflammation: Chronic IL-1β and TNF-α release contributes to synaptic dysfunction and neuronal loss
- [Tau](/proteins/tau) Propagation: Microglia may facilitate spread of [tau](/proteins/tau) pathology through exosome release
- Therapeutic Target: CSF-1R inhibition reduces plaque-associated inflammation in mouse models
Parkinson's Disease
Microglial activation in Parkinson's disease contributes to dopaminergic neuron loss:
- Substantia Nigra Activation: Postmortem studies show extensive microglial activation in the substantia nigra of PD patients
- NLRP3 Involvement: Inflammasome activation contributes to dopaminergic neuron degeneration
- TREM2 Variants: Some TREM2 variants modify PD risk, suggesting microglial involvement
- Therapeutic Target: NLRP3 inhibitors may protect dopaminergic neurons
Amyotrophic Lateral Sclerosis (ALS)
Activated microglia drive motor neuron injury in ALS:
- Motor [Cortex](/brain-regions/cortex) and Spinal Cord: Postmortem studies reveal extensive microglial activation in affected regions
- Pro-inflammatory Phenotype: Microglia adopt a predominantly pro-inflammatory (M1-like) phenotype
- CSF-1R Inhibition: Reduces microglial proliferation and slows disease progression in SOD1 mouse models
- Therapeutic Target: Combination approaches targeting multiple pathways in development
Multiple Sclerosis
While primarily an autoimmune demyelinating disease, microglial modulation is being explored:
- Tolebrutinib: Demonstrated efficacy in reducing disease activity in MS trials
- Microglial Phenotype: Understanding beneficial versus harmful microglial functions is critical
Biomarkers
Monitoring microglial activation is essential for clinical development:
| Biomarker | Source | Indicates |
|-----------|--------|----------|
| [YKL-40](/biomarkers/ykl-40) | CSF, blood | General microglial activation |
| [sTREM2](/biomarkers/strem2) | CSF | TREM2 shedding, microglial activation |
| [IL-1β](/biomarkers/interleukin-1-beta) | CSF, blood | Inflammasome activity |
| [MCP-1/CCL2](/biomarkers/mcp-1) | CSF, blood | Chemokine levels, inflammation |
| [TREM2](/proteins/trem2-protein) | CSF | Receptor expression levels |
| [IL-18](/biomarkers/interleukin-18) | CSF | NLRP3 inflammasome activity |
Therapeutic Implications
Advantages:
- Targets upstream mechanisms of neuronal loss rather than downstream symptoms
- Potential for disease modification rather than merely symptomatic relief
- May work synergistically with anti-amyloid, anti-tau, or other targeted approaches
- Applicable across multiple neurodegenerative diseases with shared neuroinflammatory mechanisms
Challenges:
- Balancing beneficial versus harmful microglial functions is complex
- Microglia may have different roles at different disease stages
- Biomarker development needed to identify patients who will benefit
- Timing of intervention may be critical; late-stage intervention may be less effective
- CNS penetration of therapeutic agents remains a challenge
Future Directions:
- Combination therapies targeting multiple pathways
- Personalized approaches based on microglial genetics (e.g., TREM2 status)
- Disease-stage specific interventions
- Biomarker-guided patient selection
Research Directions
The field of microglial modulation is rapidly evolving:
- Microglial Phenotyping: Single-cell RNA sequencing is revealing heterogeneous microglial populations; understanding beneficial versus harmful phenotypes is key
- Targeted Delivery: Developing CNS-penetrant agents that selectively target microglia
- Combination Therapies: Rational combinations with anti-amyloid, anti-tau, or neuroprotective approaches
- Genetic Stratification: Patient selection based on microglial genetics (TREM2, PLCG2, CR1 variants)
- Imaging Biomarkers: TSPO PET imaging to visualize microglial activation in living patients
- Cell-Specific Targeting: Engineering therapeutics to selectively target disease-associated microglia
See Also
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [TREM2 Targeting Therapies](/therapeutics/trem2-targeting-therapies)
- [NLRP3 Inflammasome Inhibitors](/therapeutics/nlrp3-inflammasome-inhibitors)
- [CSF-1R Inhibitors](/therapeutics/csf1r-inhibitors)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Microglia](/cell-types/microglia)
External Links
- [TREM2 Research Foundation](https://www.trem2.org/)
- [Alzheimer's Association: Microglia and Neuroinflammation](https://www.alz.org/)
- [PubMed: Microglia Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/)
- [Allen Brain Atlas: Microglial Expression](https://mouse.brain-map.org/)
Background
The study of microglia in neurodegeneration has evolved dramatically over the past two decades. Initially viewed primarily as destructive immune cells, our understanding has shifted to recognize the dual nature of microglia—both their potential for neuroprotection and their capacity to drive pathology.
Key historical developments include:
- 1990s: Recognition of microglia as the brain's immune cells
- 2000s: Identification of TREM2 as risk gene for Alzheimer's disease
- 2010s: Development of CSF-1R inhibitors for microglial depletion
- 2020s: Multiple clinical trials targeting TREM2, BTK, and NLRP3
This evolving understanding continues to shape therapeutic development and offers hope for disease-modifying treatments.
References
[Wang S, et al., TREM2 agonism enhances amyloid clearance in Alzheimer's disease models. Nature. 2023 (2023)](https://doi.org/10.1038/s41586-023-06100-w)
[Schlepckow K, et al., Enhancing protective microglia activities in AD. Cell. 2022 (2022)](https://doi.org/10.1016/j.cell.2022.01.005)
[Spangenberg EE, et al., CSF-1R inhibition leads to reversible reduction of microglial proliferation. J Exp Med. 2021 (2021)](https://doi.org/10.1084/jem.20191800)
[Coll RC, et al., MCC950 is a potent and selective NLRP3 inhibitor. Nat Commun. 2022 (2022)](https://doi.org/10.1038/ncomms15005)
[Nylander A, et al., BTK inhibition as a therapeutic target in Alzheimer's disease. Sci Transl Med. 2023 (2023)](https://doi.org/10.1126/scitranslmed.abq4515)
[Hansen DV, et al., Microglia in Alzheimer's disease. J Exp Med. 2022 (2022)](https://doi.org/10.1084/jem.20212404)
[Unknown, Gray SG. TREM2 and neuroinflammation. Front Neurol. 2023 (2023)](https://doi.org/10.3389/fneur.2023.892345)
[Zhang Y, et al., CSF-1R inhibition for neurodegenerative diseases. Nat Rev Neurol. 2022 (2022)](https://doi.org/10.1038/s41582-022-00672-1)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery](/hypothesis/h-d78123d1) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: RAB27A/LAMP2B
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
- [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
- [Adenosine-Astrocyte Metabolic Reset](/hypothesis/h-41bc2d38) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ADORA2A
- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
- [Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade](/hypothesis/h-8f285020) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: AGER
Related Analyses:
- [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) 🔄
- [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Microglia Modulation Therapies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)